Company research
Embecta Corp.
CIK 1872789Updated Sep 24, 2026
SecurityEMBC · NASDAQ · equity
Historical securities (1)
EMBCV · OTC · equity · closed Mar 31, 2022Name history
Berra Newco, Inc. · through Sep 3, 2021
EMBC price & chart
Loading TradingView…
NASDAQ:EMBC on TradingView ↗About the company
embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
In the news
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Embecta Corp. of Class Action Lawsuit and Upcoming Deadlines - EMBC ↗
EMBC INVESTOR ALERT: Embecta Corp. (EMBC) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS ↗
Recent filings
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Financial Statements and Exhibits
Items 9.01
SD filing
Completion of Acquisition or Disposition of Assets · Regulation FD Disclosure
Items 2.01, 7.01, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,090,900,000Source | 1,285,300,000Source | 1,214,400,000Source | 1,086,400,000Source |
| GoodwillUSD | 15,400,000Source | 15,600,000Source | 15,600,000Source | 15,700,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 225,500,000Source | 267,500,000Source | 326,500,000Source | 330,900,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 145,600,000Source | 193,000,000Source | 16,700,000Source | 22,200,000Source |
| Inventory, NetUSD | 178,600,000Source | 171,500,000Source | 152,100,000Source | 122,800,000Source |
| Assets, CurrentUSD | 631,400,000Source | 761,000,000Source | 749,100,000Source | 664,700,000Source |
| Operating Lease, Right-of-Use AssetUSD | 20,200,000Source | 22,600,000Source | 23,000,000Source | 6,300,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 600,000Source | 600,000Source | 600,000Source | 600,000Source |
| Additional Paid in CapitalUSD | 80,000,000Source | 52,500,000Source | 27,900,000Source | 10,000,000Source |
| Retained Earnings (Accumulated Deficit)USD | -445,600,000Source | -498,600,000Source | -541,100,000Source | -577,100,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -285,600,000Source | -292,800,000Source | -309,100,000Source | -324,900,000Source |
| Stockholders' Equity Attributable to ParentUSD | -650,600,000Source | -738,300,000Source | -821,700,000Source | -891,400,000Source |
| Liabilities and EquityUSD | 1,090,900,000Source | 1,285,300,000Source | 1,214,400,000Source | 1,086,400,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 261,500,000Source | 374,000,000Source | 353,500,000Source | 301,000,000Source |
| Operating Lease, Liability, CurrentUSD | 6,900,000Source | 6,000,000Source | 5,900,000Source | 2,000,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,200,000Source | 11,900,000Source | 15,400,000Source | 4,300,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 98,900,000Source | 134,200,000Source | 118,100,000Source | 104,300,000Source |
| Long-term Debt, Current MaturitiesUSD | 9,500,000Source | 9,500,000Source | 9,500,000Source | 9,500,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 1,388,700,000Source | 1,565,300,000Source | 1,593,900,000Source | 1,598,100,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 40,700,000Source | 36,200,000Source | 32,600,000Source | 31,700,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 31,600,000Source | 26,300,000Source | 21,500,000Source | 18,700,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -44,200,000Source | 174,700,000Source | -7,000,000Source | -122,700,000Source |
| Increase (Decrease) in InventoriesUSD | 6,100,000Source | 16,500,000Source | 28,800,000Source | 23,400,000Source |
| Deferred Income Tax Expense (Benefit)USD | 17,600,000Source | -70,600,000Source | 14,300,000Source | -26,500,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 191,700,000Source | 35,700,000Source | 67,700,000Source | 412,200,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -9,300,000Source | -15,800,000Source | -26,500,000Source | -24,000,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 9,300,000Source | 15,800,000Source | 26,500,000Source | 23,600,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 5,700,000Source | 3,000,000Source | 3,600,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -226,700,000Source | -73,400,000Source | -48,700,000Source | -48,000,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 35,000,000Source | 34,500,000Source | 34,400,000Source | 8,600,000Source |
| Repayments of Long-term DebtUSD | 184,600,000Source | 34,600,000Source | 9,500,000Source | 4,800,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -45,600,000Source | -52,300,000Source | -4,400,000Source | 330,900,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 228,600,000Source | 274,200,000Source | 326,500,000Source | 330,900,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 103,800,000Source | 117,700,000Source | 111,000,000Source | 38,900,000Source |
| Income Taxes Paid, NetUSD | 50,100,000Source | 29,100,000Source | 30,400,000Source | 15,600,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 31,800,000Source | 26,600,000Source | 21,900,000Source | 18,700,000Source |
| Amortization of Debt Issuance CostsUSD | 9,100,000Source | 6,900,000Source | 6,400,000Source | 3,200,000Source |
| Amortization of Intangible AssetsUSD | 1,100,000Source | 1,100,000Source | 1,200,000Source | 700,000Source |
| DepreciationUSD | 38,100,000Source | 34,900,000Source | 31,500,000Source | 31,000,000Source |
| GoodwillUSD | 15,400,000Source | 15,600,000Source | 15,600,000Source | 15,700,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | 40,900,000Source | -34,100,000Source | 35,300,000Source | 33,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | 95,400,000Source | 78,300,000Source | 70,400,000Source | 223,600,000Source |
| Nonoperating Income (Expense)USD | 1,500,000Source | -10,300,000Source | -8,800,000Source | -6,800,000Source |
| Operating ExpensesUSD | 434,700,000Source | 568,400,000Source | 528,400,000Source | 465,300,000Source |
| Other Operating Income (Expense), NetUSD | -700,000Source | — | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | 0Source | 0Source | 1,450,000,000Source |
| Restructuring CostsUSD | 15,700,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,080,400,000Source | 1,123,100,000Source | 1,120,800,000Source | 1,129,500,000Source |
| Cost of RevenueUSD | 403,600,000Source | 387,900,000Source | 370,900,000Source | 354,600,000Source |
| Selling, General and Administrative ExpenseUSD | 332,000,000Source | 365,100,000Source | 341,300,000Source | 294,800,000Source |
| Operating Income (Loss)USD | 242,100,000Source | 166,800,000Source | 221,500,000Source | 309,600,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 136,300,000Source | 44,200,000Source | 105,700,000Source | 256,600,000Source |
| Income Tax Expense (Benefit)USD | 40,900,000Source | -34,100,000Source | 35,300,000Source | 33,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | 95,400,000Source | 78,300,000Source | 70,400,000Source | 223,600,000Source |
| Earnings Per Share, BasicUSD per share | 1.64Source | 1.36Source | 1.23Source | 3.92Source |
| Earnings Per Share, DilutedUSD per share | 1.62Source | 1.34Source | 1.22Source | 3.89Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 58,309,000Source | 57,681,000Source | 57,248,000Source | 57,024,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 58,915,000Source | 58,326,000Source | 57,758,000Source | 57,461,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,100,000Source | 1,100,000Source | 1,200,000Source | 700,000Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0.6Source | 0.6Source | 0.15Source | 0.15Source |
| Current Income Tax Expense (Benefit)USD | 23,300,000Source | 36,500,000Source | 21,000,000Source | 59,500,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Gross ProfitUSD | 676,800,000Source | 735,200,000Source | 749,900,000Source | 774,900,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -39,000,000Source | -116,700,000Source | -100,900,000Source | -29,100,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -107,300,000Source | -112,300,000Source | -107,000,000Source | -46,200,000Source |
| Interest Income, OtherUSD | 6,000,000Source | 12,000,000Source | 9,400,000Source | — |
| Nonoperating Income (Expense)USD | 1,500,000Source | -10,300,000Source | -8,800,000Source | -6,800,000Source |
| Operating ExpensesUSD | 434,700,000Source | 568,400,000Source | 528,400,000Source | 465,300,000Source |
| Other General ExpenseUSD | 65,400,000Source | 124,500,000Source | 99,400,000Source | 44,700,000Source |
| Other Operating Income (Expense), NetUSD | -700,000Source | — | — | — |
| Research and Development ExpenseUSD | 37,300,000Source | 78,800,000Source | 85,200,000Source | 66,900,000Source |
| Restructuring CostsUSD | 15,700,000Source | — | — | — |
Filing attachments
q32026ex-991.htm · 8-K · 2026-08-07
EX-99.1 2 q32026ex-991.htm EX-99.1 Document FOR IMMEDIATE RELEASE Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Aug 7, 2026 (GLOBE NEWSWIRE) - Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2026. "Our third quarter results improved significantly on a sequential basis, with revenue increasing approximately $50 million, GAAP …
Read attachment ↗q320268kaex-991.htm · 8-K/A · 2026-07-31
EX-99.1 3 q320268kaex-991.htm EX-99.1 Document OWEN MUMFORD HOLDINGS LIMITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2025 OWEN MUMFORD HOLDINGS LIMITED (COMPANY NO: 555254) CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2025 INDEX Page 4 Consolidated Statement of Comprehensive Income 5 Consolidated Statement of Changes in Equity 6 Consolidated Balance Sheet 7 Consolidated Cash Flow Statement …
Read attachment ↗q320268kaex-992.htm · 8-K/A · 2026-07-31
EX-99.2 4 q320268kaex-992.htm EX-99.2 Document UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On May 15, 2026, Embecta Corp. (“Embecta”) completed its previously announced acquisition (the “Transaction”) of Owen Mumford Holdings Limited (“Owen Mumford”), pursuant to the terms of the Agreement for the Sale and Purchase (“the Agreement”), dated as of March 19, 2026. Owen Mumford is a privately held, UK-based innovator and manufacturer of medical devices and drug-d…
Read attachment ↗q22026ex-991.htm · 8-K · 2026-05-05
EX-99.1 2 q22026ex-991.htm EX-99.1 Document FOR IMMEDIATE RELEASE Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results Lowers fiscal year 2026 financial guidance due to dynamics impacting U.S. business; updated guidance also includes impact of the impending Owen Mumford acquisition Initiated a review of cost structure and organizational footprint Announced Board authorization of a three-year $100 million share repurchase program and a reduction in the dividend Anticipates…
Read attachment ↗